TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34121642
Drug: Iso-energetic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso-energetic placebo (PR; n 15, 0 g protein)
Study: 32066607
Drug: OHP (Optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OHP (Optimal Health Programme) plus treatment as usual
Study: 33142545
Drug: Selenium-enriched yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-enriched yeast (SY) supplementation at 0.1, 0.2, 0.3, or 0.4 mg/kg
Study: 33142545
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (SS) supplementation at 0.3 mg/kg
Study: 35124285
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (pronator teres rerouting, FCU transfer to ECRB, fractional lengthening)
Study: 32304832
Drug: Ragweed SLIT-tablet
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragweed SLIT-tablet (12 Amb a 1-Unit)
Study: 34847501
Drug: Risperidone ISM®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone ISM® 75 or 100 mg once-monthly intramuscular injections for 12 months
Study: 34586227
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation with ranibizumab injections
Study: 33913639
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g)
Study: 33845034
Drug: Tisotumab vedotin
Normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tisotumab vedotin 2.0 mg/kg intravenously once every 3 weeks until disease progression or unacceptable toxicity
Study: 36113394
Drug: Sertraline or
Normalized name: sertraline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline or interpersonal psychotherapy for 14 weeks (T2)
Study: 36113394
Drug: Treatment received
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment received (Sertraline or interpersonal psychotherapy)
Study: 34212560
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine plus intravenous remifentanil (DEX-REMI group)
Study: 34212560
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil only (REM group)
Study: 35350988
Drug: Levosimendan +
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan + Shenfu injection (SFI)
Study: 33823265
Drug: Lower extremity
Normalized name: lymphedema garments, lower extremity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower extremity intermittent negative pressure (INP) of -40 mm Hg for one hour twice daily for 24 weeks
Study: 33871363
Drug: Probiotic mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic mixture (L. plantarum PBS067, L. reuteri PBS072, L. rhamnosus LRH020) for 56 days
Study: 36040071
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B gel (LAmB gel) for 28 days
Study: 36040071
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for 28 days
Study: 36040071
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B gel (LAmB gel) for 56 days
Study: 36071664
Drug: Tablet for
Normalized name: TABLET FOR SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for multimodal learning
Study: 36071664
Drug: Nurse explanation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse explanation on home self‐injection of enoxaparin sodium (Control)
Study: 33787151
Drug: Yangxue Qingnao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangxue Qingnao Granules combined with conventional anti-hypertensive agents
Study: 34862359
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (Tx0) for 3 weeks
Study: 33054008
Drug: Traditional conservative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional conservative therapy and different wavelengths laser therapy (LT) course
Study: 33054008
Drug: Traditional conservative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional conservative therapy and intravenous laser blood irradiation (ILBI) (λ - 635 nm)
Study: 33054008
Drug: Traditional conservative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional conservative therapy only
Study: 35710594
Drug: Established antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established antihypertensive therapy
Study: 35730245
Drug: EsoduoⓇ (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg)
Study: 35730245
Drug: NexiumⓇ (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: NexiumⓇ (esomeprazole 20 mg)
Study: 34124929
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Processing Therapy (CPT)
Study: 32198939
Drug: Branebrutinib (0.3-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branebrutinib (0.3-30 mg for SAD; 0.3-10 mg for JMAD)
Study: 32198939
Drug: Branebrutinib (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branebrutinib (daily for 14 days in MAD)
Study: 32198939
Drug: Branebrutinib (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branebrutinib (single 10 mg dose)
Study: 35869266
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy then momelotinib
Study: 32158202
Drug: Progressive Resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Resistance Training (PRT) - 9-week program, twice a week
Study: 34397698
Drug: Combined Naikan
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Naikan therapy (NT) and Morita therapy (MT) for 7 consecutive weeks
Study: 34397698
Drug: Normal medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal medical treatments without NT and MT
Study: 36173238
Drug: Insulin-only configuration
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-only configuration of the iLet® bionic pancreas (BP)
Study: 35337193
Drug: Development and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development and Well-Being Assessment (DAWBA) as an adjunct to referral letters
Study: 35461285
Drug: Antisecretory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory factor (Salovum®) as a food supplement
Study: 33596852
Drug: Cranberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry beverage consumed daily for 24 weeks
Study: 32513257
Drug: Topical Timoptic-XE®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Timoptic-XE® (timolol maleate ophthalmic gel forming solution)
Study: 36917429
Drug: Injection site
Normalized name: Dual Injection Site
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection site reactions
Study: 33001232
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of pioglitazone for 16 weeks
Study: 33247012
Drug: 99DOTS-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99DOTS-based treatment supervision
Study: 34107933
Drug: Oral rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehabilitation procedures
Study: 34107933
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral rehabilitation during the study period)
Study: 34277476
Drug: M+P (Miltefosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: M+P (Miltefosine 50 mg BID and Pentoxifylline 400 mg TID)
Study: 34277476
Drug: A+P (Antimonials
Approvals — FDA: no, EMA: no, PMDA: no
Description: A+P (Antimonials 20 mg Sb+V/kg/day IV and Pentoxifylline 400 mg TID)
Study: 34277476
Drug: Treatment comparison
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment comparison (M+P vs A+P)
Study: 36112655
Drug: 0.9 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 mg/kg Se methionine
Study: 36112655
Drug: 0.6, 0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6, 0.3, and 0.0 mg/kg Se methionine
Study: 32695229
Drug: Resveratrol 100
Normalized name: resveratrol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 100 mg capsule daily for 3 months
Study: 32645251
Drug: 1% Sandalore®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Sandalore® solution
Study: 33243284
Drug: M. communis
Approvals — FDA: no, EMA: no, PMDA: no
Description: M. communis preparation in addition to conventional therapy
Study: 39186268
Drug: Modified directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified directly observed therapy
Study: 32649736
Drug: GLS4 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 (120 mg) and ritonavir (100 mg)
Study: 32649736
Drug: GLS4 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS4 (240 mg) and ritonavir (100 mg)
Study: 36122259
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into coracohumeral ligament (CHL) and inferior glenohumeral capsule (IGHC)
Study: 36122259
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection into posterior glenohumeral recess (PGHR)
Study: 34429340
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (240 mg)
Study: 34321304
Drug: Dural sealant
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dural sealant patch (DSP)
Study: 37480877
Drug: Atrial shunt
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial shunt therapy (Corvia Medical, Inc IASD System II)
Study: 37480877
Drug: Patch-detected AF
Normalized name: Canesten AF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch-detected AF during follow-up
Study: 616168499
Drug: Nefopam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (0.3 mg/kg bolus followed by continuous infusion at 65 micro g/kg/h)
Study: 616168499
Drug: Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3 mg/kg bolus followed by continuous infusion at 180 micro g/kg/h)
Study: 616168499
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (bolus and infusion equal to ketamine group)
Study: 36126454
Drug: Afatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30 mg or 40 mg) without PPI (period A)
Study: 36126454
Drug: Afatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30 mg or 40 mg) with 40 mg esomeprazole (period B)
Study: 36126454
Drug: Afatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (30 mg or 40 mg) three hours after esomeprazole intake (period C)
Study: 33315169
Drug: Short-term dual
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term dual antiplatelet therapy (DAPT) (at most 6 months)
Study: 33315169
Drug: Long-term dual
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term dual antiplatelet therapy (DAPT) (at least 12 months)
Study: 33447025
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol 100/25 μg once daily
Study: 34662548
Drug: Sbv +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sbv + topical BC bio-curatives
Study: 35833676
Drug: Trauma Center
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Center Trauma-Sensitive Yoga (TCTSY), 10 weekly sessions
Study: 35833676
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT), 12 weekly sessions
Study: 34221251
Drug: 3MDR therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3MDR therapy
Study: 32474728
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg
Study: 35091036
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of weight-based (15 mg/kg) vancomycin
Study: 36032232
Drug: Taijiquan combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taijiquan combined with acupoint pressing (treatment before sleep)
Study: 36032232
Drug: Taijiquan combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taijiquan combined with acupoint pressing (treatment after sleep)
Study: 36032232
Drug: Taijiquan combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taijiquan combined with acupoint pressing (both treatment groups)
Study: 35139161
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin withdrawal (placebo)
Study: 35139161
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of intravenous immunoglobulin treatment (control)
Study: 33141327
Drug: Group handwashing
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group handwashing facilities and daily group handwashing and toothbrushing activities
Study: 35191268
Drug: Micro needle
Normalized name: Salicylic Acid 0.002 TOPICAL PATCH [Egg micro needle soothing]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro needle knife therapy
Study: 35191268
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug (Merislon, 6 mg, 3 times a day for 2 weeks)
Study: 35123457
Drug: Fixed-dose inhaled
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose inhaled corticosteroids (ICS) as control
Study: 35123457
Drug: Taper and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper and subsequently stop ICS
Study: 35332685
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MT) additional over inspiratory muscle training (IMT) at 40% of maximal inspiratory pressure (MIP) for 12 weeks (n = 30)
Study: 34365905
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GOS (10-15 grams/day)
Study: 34365905
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GOS (15-20 grams/day)
Study: 34365905
Drug: GOS (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS (both doses)
Study: 35670987
Drug: Triggered escalating
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triggered escalating real‐time adherence (TERA) intervention with remote coaching, electronic dose monitoring (EDM), and outreach for missed/delayed doses
Study: 32503806
Drug: Simplified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified treatment schedules, telemedicine facilitation, decreased data collection requirements
Study: 33720997
Drug: Daily SMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily SMS reminders about insulin injections
Study: 32709172
Drug: Bilateral ultrasound-guided
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral ultrasound-guided Erector Spinae Plane (ESP) block with 20 mL of bupivacaine 0.375% plus 5 ug/mL adrenaline (1:200000)
Study: 34817667
Drug: Pharmacist-led medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led medication reconciliation at hospital admission
Study: 33486475
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration (0.9% saline at 0.5 mL/(kg·h))
Study: 32105310
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin (FC) <250 µg/g
Study: 32105310
Drug: CRP <5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP <5 mg/L
Study: 32105310
Drug: Fecal calprotectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal calprotectin <250 µg/g, CRP <5 mg/L, and CDAI <150
Study: 35313276
Drug: Dietary intake
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intake of N3-rich foods and supplement compliance
Study: 33814320
Drug: Nasal high-flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high-flow therapy (NHFT)
Study: 34551998
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LD‐MTX) 15-20 mg/week
Study: 34551998
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LD‐MTX)
Study: 32565333
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 mg taken 1 hour before treatment
Study: 32565333
Drug: Nonibuprofen (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonibuprofen (no analgesics taken before treatment)
Study: 32565333
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (4 patients undergoing endodontic therapy for prosthodontic reasons, no analgesics)
Study: 33314332
Drug: Microtextured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtextured implants with a 3.6mm-long internal-connection machined collar
Study: 33314332
Drug: Machined implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machined implants with a 1.2mm-long external-connection machined collar
Study: 33314332
Drug: Microtextured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtextured implants with a 1.2mm-long external-connection machined collar
Study: 33314332
Drug: Internal-connection microtextured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal-connection microtextured implants
Study: 33314332
Drug: External-connection microtextured
Approvals — FDA: no, EMA: no, PMDA: no
Description: External-connection microtextured implants
Study: 33314332
Drug: All implant
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implant types
Study: 32381373
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (14 mg)
Study: 33293295
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (monthly, individual CHV home visits)
Study: 32214373
Drug: Personalized metabolism-informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized metabolism-informed care (MIC)
Study: 35596182
Drug: Olaparib as
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib as maintenance therapy
Study: 35596182
Drug: Newly derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly derived reference values for treatment-naïve mPC patients
Study: 34530495
Drug: Individual reminiscence
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual reminiscence therapy for 8 weeks during home visits (once a week)
Study: 32067533
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (4.0-5.1 mg daily)
Study: 35410783
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative laxatives
Study: 33663414
Drug: Monthly sessions
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly sessions regarding physical activity and health-related topics for 6 months (Control)
Study: 35379537
Drug: Case Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case Management with Problem-Solving Therapy (CM-PST)
Study: 32171064
Drug: Maintenance budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance budesonide (200 μg twice per day) plus as-needed salbutamol (two inhalations of 100 μg)
Study: 32171064
Drug: As-needed salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As-needed salbutamol (two inhalations of 100 μg)
Study: 32171064
Drug: As-needed budesonide-formoterol
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed budesonide-formoterol (one inhalation of 200 μg budesonide and 6μg formoterol)
Study: 35074887
Drug: Group-administered recovery
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered recovery programme (3 sessions, 2 weeks apart)
Study: 33038833
Drug: DHA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (50 mg/Kg/day)
Study: 32871950
Drug: Conbercept 6-monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conbercept 6-monthly loading dose injection and PRN (6+PRN)
Study: 32871950
Drug: Conbercept 3-monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conbercept 3-monthly loading dose injection and PRN (3+PRN)
Study: 35502861
Drug: Cold Acclimation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Acclimation (CA) - immersion to the chest in 14°C water for ≥120 min daily over a 5-day period
Study: 34391917
Drug: Lidocaine (L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (L group)
Study: 35460249
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) supplementation (weekly 50,000 IU for 4 weeks followed by daily 2000 IU until 1 year)